The Prevalence and Cost Implications of Bloodstream Infection Producing Extended-Spectrum Beta-Lactamase (ESBL) in Adult Patients at Dr. Soetomo General Academic Hospital
Abstract
Bloodstream infections (BSIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae represent a growing concern in healthcare settings, particularly in tertiary hospitals. These infections are associated with limited therapeutic options, increased mortality, and rising healthcare costs. This study aimed to describe the clinical, microbiological, and economic characteristics of adult inpatients diagnosed with hospital-acquired (HA) BSIs due to ESBL-producing Enterobacteriaceae at Dr. Soetomo General Academic Hospital from January 1 to December 31, 2024. A cross-sectional study was conducted using retrospective data from adult inpatients (≥18 years) with confirmed HA-BSIs caused by ESBL-producing Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Only the first positive blood culture per patient was analyzed. Community-acquired infections and non-Enterobacteriaceae organisms were excluded. The most frequent pathogen was Escherichia coli ESBL, especially among patients from medical wards. BSIs occurred predominantly in medical and intensive care units. Notably, microbiological confirmation of ESBL-producing organisms led to higher claim reimbursements through the national health insurance system, yielding a positive cost margin despite longer hospital stays and expensive treatment regimens. In conclusion, ESBL-producing Enterobacteriaceae remain a major challenge in managing HA-BSIs at Dr. Soetomo General Academic Hospital. While clinically burdensome, accurate microbiological diagnosis also supports optimal resource utilization and insurance claim efficiency in the hospital setting.
Full text article
References
Bush, K., & Bradford, P. A. (2016). β-Lactams and β-lactamase inhibitors: An overview. Cold Spring Harbor Perspectives in Medicine, 6(8), a025247. https://doi.org/10.1101/cshperspect.a025247
Busse, R. (2012). Do diagnosis-related groups explain variations in hospital costs and length of stay? - Analyses from the EURODRG project for 10 episodes of care across 10 European countries. Health Economics, 21(Suppl.2), 1–5. https://doi.org/10.1002/hec
CDC. (2021). Background of the Management of Multidrug- Resistant Organism in Healthcare Settings Guideline, https://www.cdc.gov/infection-control/hcp/mdro-management/background.html
Direktorat Jenderal Pelayanan Kesehatan Kemenkes RI. (2022). Panduan pengajuan klaim Jaminan Kesehatan Nasional (JKN) untuk RS rujukan kelas A dan B. Jakarta: Kemenkes RI.
Indonesian Ministry of Health. (2023). Pedoman Nasional Pengendalian Resistensi Antimikroba di Rumah Sakit. Jakarta: Kemenkes RI.
Jean, S. S., Hsueh, P. R., Lee, W. S., & Yu, C. J. (2022). Hospital-acquired bloodstream infections: Current trends and challenges in the Asia-Pacific region. Journal of Global Antimicrobial Resistance, 29, 321–329. https://doi.org/10.1016/j.jgar.2021.08.011
Kaye, K. S., Pogue, J. M., Tran, T. B., Nation, R. L., & Li, J. (2021). Agents of last resort: The role of polymyxins and newer antibiotics in treating resistant Gram-negative infections. Current Opinion in Infectious Diseases, 34(6), 519–528. https://doi.org/10.1097/QCO.0000000000000792
Lee, C. H., Lee, M. H., Ko, W. C., & Chang, C. M. (2019). Epidemiology and clinical significance of bloodstream infections caused by ESBL-producing Enterobacteriaceae. Journal of Microbiology, Immunology and Infection, 52(4), 515–524. https://doi.org/10.1016/j.jmii.2018.12.005
Meletis, G. (2016). Carbapenem resistance: Overview of the problem and future perspectives. Therapeutic Advances in Infectious Disease, 3(1), 15–21. https://doi.org/10.1177/2049936115621709
NICE. (2016). Suspected sepsis: recognition, diagnosis and early management. NICE guideline. www.nice.org.uk/guidance/ng51.
Paterson, D. L., & Bonomo, R. A. (2005). Extended-spectrum β-lactamases: A clinical update. Clinical Microbiology Reviews, 18(4), 657–686. https://doi.org/10.1128/CMR.18.4.657-686.2005
Ritchie, H., & Roser, M. (2019). Causes of death. Our World in Data. https://ourworldindata.org/causes-of-death
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, Á. (2018). Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clinical Microbiology Reviews, 31(2), e00079-17. https://doi.org/10.1128/CMR.00079-17
Russo, T. A., & Johnson, J. R. (2003). Medical and economic impact of extraintestinal infections due to Escherichia coli: Focus on an increasingly important endemic problem. Microbes and Infection, 5(5), 449–456. https://doi.org/10.1016/S1286-4579(03)00049-2
Schwaber, M. J., & Carmeli, Y. (2007). Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 60(5), 913–920. https://doi.org/10.1093/jac/dkm318
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021). Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 72(7), e169–e183. https://doi.org/10.1093/cid/ciaa1478
World Health Organization. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12
Yap, P. S. X., Ahmad Kamar, A., Chong, C. W., & Yap, I. K. S. (2021). Risk factors of bloodstream infections caused by multidrug-resistant organisms in Asia. Infectious Disease Reports, 13(1), 80–91. https://doi.org/10.3390/idr13010010
Authors
Copyright (c) 2025 Neneng Dewi Kurniati, Irwan Syahrir, Musa Ghufron
This work is licensed under a Creative Commons Attribution 4.0 International License.
Qanun Medika by FK UM Surabaya is liscence under Lisensi Creative Commons Atribusi 4.0 Internasional.